Search - tctmd.com

Displaying 1 - 20 of 139

Sort: Relevancy | Date

News Industry News

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

October 29, 2025

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Daily News

European Experts Provide Advice on Managing CV Effects of COVID-19

Todd Neale

September 19, 2025

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Todd Neale

August 13, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2025

Shelley Wood

February 28, 2025

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

L.A. McKeown

November 11, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

Presentation TCT 2024

TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus

Presenter: Daria Feshchenko

October 28, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2024

Shelley Wood

May 31, 2024

News Conference News EuroPCR 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Michael O'Riordan

May 14, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Features

Going Solo: Can TAVI Be Performed Without a Surgical Safety Net?

Michael O'Riordan

January 22, 2024

News Daily News

Aspirin Use Tied to Slower AAA Progression

Todd Neale

December 20, 2023

Presentation TCT 2023

TCT 158: The Impact of Sex And Age On Long-term Outcome After Percutaneous Coronary Interventions – A Pooled Analysis Of The Randomized Controlled SORT OUT Trials

Presenter: Emil Holck

October 26, 2023

Presentation TCT 2023

TCT 79: Impact of sex on clinical outcomes in patients undergoing complex percutaneous coronary angioplasty ((from the e-ULTIMASTER Study).

Presenter: Gemina Doolub

October 26, 2023

Presentation TCT 2023

TCT 307: Percutaneous Coronary Intervention Outcomes Stratified by Body Mass Index. Are Obesity Classes Created Equally? A Retrospective Population-Based Study

Presenter: Carlos Gaibor

October 26, 2023

Presentation TCT 2023

TCT 160: Comparative Effectiveness of Moderate-intensity Statin with Ezetimibe Combination Therapy Versus High-intensity Statin Monotherapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study

Presenter: Ji-Yong Jang

October 25, 2023

TCT 50: Statin and Ezetimibe Combination Therapy Versus Statin Monotherapy for Cardiovascular Outcomes Among Patients Undergoing PCI

Presentation TCT 2023

TCT 50: Statin and Ezetimibe Combination Therapy Versus Statin Monotherapy for Cardiovascular Outcomes Among Patients Undergoing Percutaneous Coronary Intervention: A Nationwide, Retrospective, Population-based Study Using National Health Insurance Data…

Presenter: Young-Hoon Seo

October 25, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

Advertisement

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

European Experts Provide Advice on Managing CV Effects of COVID-19

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

TCTMD’s Top 10 Most Popular Stories for February 2025

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus

August 2024 Dispatch for the CV Team

TCTMD’s Top 10 Most Popular Stories for May 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Going Solo: Can TAVI Be Performed Without a Surgical Safety Net?

Aspirin Use Tied to Slower AAA Progression

TCT 158: The Impact of Sex And Age On Long-term Outcome After Percutaneous Coronary Interventions – A Pooled Analysis Of The Randomized Controlled SORT OUT Trials

TCT 79: Impact of sex on clinical outcomes in patients undergoing complex percutaneous coronary angioplasty ((from the e-ULTIMASTER Study).

TCT 307: Percutaneous Coronary Intervention Outcomes Stratified by Body Mass Index. Are Obesity Classes Created Equally? A Retrospective Population-Based Study

TCT 160: Comparative Effectiveness of Moderate-intensity Statin with Ezetimibe Combination Therapy Versus High-intensity Statin Monotherapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study

TCT 50: Statin and Ezetimibe Combination Therapy Versus Statin Monotherapy for Cardiovascular Outcomes Among Patients Undergoing Percutaneous Coronary Intervention: A Nationwide, Retrospective, Population-based Study Using National Health Insurance Data…

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content